NCT05704543View on ClinicalTrials.gov

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine Extended-Release Injection

Administered as a subcutaneous injection.

Trial Locations (6)

33016

Miami Lakes Medical Research, Miami Lakes

33024

Research Centers of America, Hollywood

73112

Rivus Wellness and Research Institute, Oklahoma City

75080

Pillar Clinical Research, LLC, Richardson

75115

InSite Clinical Research, LLC, DeSoto

92103

Artemis Institute for Clinical Research, San Diego

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT05704543 - Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations | Biotech Hunter | Biotech Hunter